The FDA issued a warning letter to Neogen Corporation on September 29, 2026, following an investigation linking its veterinary wound care product Neogen Vet HYCOAT to at least 20 horse deaths from serious infections. The contaminated sterile solution represents the largest number of horse deaths associated with a quality defect in an FDA-regulated veterinary product. Neogen initiated a voluntary recall in January 2026. The announcement triggered a 7.22% stock price decline. Pomerantz LLP is investigating potential securities fraud claims on behalf of investors.

The Medical Products industry faces moderate growth prospects with resilient healthcare demand offset by tariff pressures and manufacturing costs. ICU Medical shows strong momentum in infusion systems with improving earnings, Neogen benefits from commercial execution improvements in food and animal safety, while Trulieve Cannabis expects growth acceleration from new markets like Georgia and Texas despite Florida seasonal softness.

Neogen reported Q1 2026 revenue of $222.8 million, up 6.5% year-over-year, beating the consensus estimate of $208.09 million by 7.07%. EPS came in at $0.08 versus the estimate of $0.05, representing a 60% surprise. The company showed strong performance across most segments, with Food Safety revenue at $163.2 million and Animal Safety at $59.6 million, both exceeding analyst expectations. The stock has a Zacks Rank #2 (Buy) rating.

Neogen reported quarterly earnings of $0.08 per share, beating consensus estimates of $0.05 and marking a 60% earnings surprise. The company also exceeded revenue expectations with $222.8 million, up from $209.19 million year-over-year. Despite strong performance, Neogen's Medical-Products industry ranks in the bottom 35% of Zacks industries. The stock has gained 86.1% year-to-date and holds a Zacks Rank #2 (Buy) rating.

Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

Kestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.

Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.

Neogen stock surged over 31% after posting a beat-and-raise fiscal Q2 earnings report. Despite revenue declining nearly 3% year-over-year to $224.7 million and net income dropping slightly, the company crushed analyst expectations and raised full-year guidance. However, the analyst expresses caution about the stock's future, noting the revenue decline and suggesting investors may be overexcited about the results.

Neogen Corporation has renewed its sponsorship with US Equestrian, focusing on educational materials about equine botulism prevention and treatment. The collaboration aims to raise awareness about the potentially deadly neurotoxin and promote horse health through scientific resources.

A class action lawsuit has been filed against Neogen Corporation alleging false and misleading statements about company integration and financial performance during the period of January 5, 2023 to June 3, 2025.